We investigated a possible association between the C373G (Leu125Val) polymorphism in the platelet endothelial cell adhesion molecule-1 (PECAM-1) and myocardial infarction (MI) among patients with type 2 diabetes (T2DM) in the Slovene population (Caucasians). The study population of this cross-sectional analysis consisted of 452 subjects with T2DM lasting more than 10 years: 142 patients with MI (MI group) and 310 patients (control group) with no history of coronary diseases. There were significant differences of PECAM-1 genotype distribution in patients with MI (CC=28.2%, CG=47.2% and GG=24.6%) compared with subjects in the control group (CC=17.1%, CG=53.5% and GG=29.4%). The multivariate model showed that the CC genotype of the PECAM-1 gene polymorphism (C373G) (OR=1.9, 95% CI 1.2-3.0, P=0.007) was an independent risk factor for MI. The C allele frequency was also significantly higher (P=0.005) in MI (51.8%) than in control subjects (41%). In addition, our study revealed the connection between smoking habits, the duration of diabetes and the total and LDL cholesterol serum levels and MI in Slovene T2DM patients. We suggest that the tested polymorphism of PECAM-1 (C373G) is associated with MI. Therefore, it might be used as genetic marker of MI in T2DM.
Introduction
Coronary artery disease (CAD) is one of the main causes for morbidity and death in the developed world and in the developing countries [1] [2] [3] . One of the major and independent risk factors for the development of CAD and subsequent myocardial infarction (MI) is type 2 diabetes (T2DM) [4] . T2DM is characterized by endothelial dysfunction, increased thrombogeneisity [5] and abnormal chronic inflammatory response [6] that lead to atherosclerosis.
Atherosclerosis is denoted by the recruitment of circulating leukocytes and monocytes to the inflamed vascular wall. It is predominantly mediated by a group of cellular adhesion molecules expressed on the cell surface, including intracellular cell adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and platelet endothelial cell adhesion molecule-1 (PECAM-1, CD 31) [7] [8] [9] . PECAM-1, a member of the immunoglobulin (Ig) superfamily, is expressed on the surface of monocytes, neutrophils, some T lymphocytes subsets, platelets and endothelial cells [10] [11] [12] . It plays an important role in the transendothelial migration of monocytes and leukocytes, plaque formation and thrombosis [11, 13] .
PECAM-1 is a transmembrane glycoprotein with 6 Ig-like (homology) extracellular domains (encoded by exons 3-8), a transmembrane domain (encoded by exon 9) and a cytoplasmatic tail (encoded by exons [10] [11] [12] [13] [14] [15] [16] [14, 15] . Exon 3 encodes for the first extracellular Ig-like domain and exon 8 encodes for the sixth extracellular Ig-like domain. PECAM-1 forms a homophilic binding via its first or the first plus the second extracellular Ig-like domains or heterophilic bindings with other molecules to mediate a cell-cell adhesion [16] [17] .
The PECAM-1 gene polymorphisms (Leu-125-Val, Ser563Asn) have been mainly reported in connection with CAD occurrence in different ethnic groups [18] [19] [20] [21] [22] [23] [24] . To our knowledge, there are no prior studies which investigated the association between PECAM-1 gene polymorphism C373G (Leu125Val) and MI in patients with T2DM.
The object of the study was to determine a possible connection between the PECAM-1 gene polymorphism Leu125Val (C373G) and MI among patients with T2DM in the Slovene population (Caucasians).
Experimental Procedures
The study population of this cross-sectional association study consisted of 452 subjects with diabetes lasting more than 10 years: 142 with MI (MI group) and 310 subjects in the control group with no history of CAD, no signs of ischemic changes on electrocardiogram and no ischemic changes during submaximal stress testing [25] . Subjects with T2DM came from cardiologic outpatient department (MI group) and from diabetologic outpatient department (control group). The diagnosis of MI was made according to the criteria by the World Health Organization [26] . Patients with MI were included in the study 1-9 months after the acute event. Patients and control subjects came from independent families. All the subjects enrolled in the study were Slovenes of Slavic origin. After an informed consent was obtained from the patients with MI and controls (subjects with T2DM without CAD), a detailed interview was made. Arterial hypertension, sex and cigarette smoking were defined as binary variables. Patients with MI and subjects in the control group were classified as having T2DM according to the current American Diabetes Association criteria for the diagnosis and the classification of the diabetes Expert Committee. The body mass index (BMI) was calculated as weight in kilograms divided by the height in square meters. The total cholesterol, low density lipoproteins (LDL), high density lipoproteins (HDL) and triglycerides were determined by standard biochemical methods.
The single nucleotide polymorphism (SNP) C373G (Leu125Val) at exon 3 of PECAM-1 was evaluated with the polymerase chain reaction (PCR) as described previously [18] .
Statistical analysis
Differences in mean values were analyzed by unpaired Student's t-test and presented as means ± standard deviation (SD). Chi-square test was used to compare discrete variables and genotype distributions. Genotypic odds ratios (OR) for MI with 95% confidence intervals with two-tailed p values were calculated by multiple logistic regression analysis adjusted for cardiovascular risk factors (smoking, sex, diabetes duration, age, LDL cholesterol, and PECAM-1 C373G). Statistical analysis was performed using the SPSS program for Windows version 15 (SPSS Inc. Chicago, Illinois).
Assuming a significance level of 0.05, frequency of risk allele of 0.17 in the control group and of 0.28 in the MI group, the power of our study sample (142 cases, 310 controls) was 83%. Statistical analysis was performed using the SPSS program for Windows version 15 (SPSS Inc. Illinois).
Results
The characteristics of patients with T2DM in the MI and in the control group are shown in 
Genotyping for C373 (Leu125Val) polymorphism
The distribution of the PECAM-1 gene polymorphism C373G is shown in Table 2 . The genotype distribution (Table 2 ) of the PECAM-1 polymorphism C373G in the MI group and in the control group were compatible with the Hardy-Weinberg expectations (MI group: χ 2 =0.43, P=0.51; control group: χ 2 =2.36, P=0.12). We found significant differences in frequencies of the genotypes CC, CG and GG in the MI and in the control group ( Table 2 ). The frequency of the CC genotype was significantly higher in the MI group (28.2%) compared to the control group (17.1%). A similar trend was also observed in the allele frequencies, where the C allele frequency was significantly higher (P=0.005) in MI (51.8%) than in control subjects (41%) ( Table 2 ).
The multivariate model shows that the CC genotype of the PECAM-1 gene polymorphism (C373G) (OR=1.9, 95% CI 1.2-3.0, P=0.007) was an independent risk factor for MI (Table 3 ).
Discussion
In the cross-sectional study we demonstrated that the PECAM-1 gene polymorphism C373G (Leu125Val) is an independent risk factor for MI in patients with T2DM in the Slovene population (Caucasians). However, not only the PECAM-1 polymorphism but also smoking habits, age and the duration of diabetes have also been demonstrated to be independent risk factors for MI in Slovene T2DM patients. Table 3 . Logistic regression analysis for the association with MI among type 2 diabetic patients.
PECAM-1 is a 130 kDa member of the immunoglobulins. It plays an important role in the adhesion of leukocytes and monocytes [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] by modulating the affinity of integrins [28] , and in their transendothelial migration in response to inflammatory regulators [16, 29, 30] .
The Leu125Val (C373G) and Ser563Asn (G1688A) polymorphisms in the PECAM-1 coding sequence have been mainly reported in relation to cardiovascular diseases [18, [20] [21] [22] [23] [24] . But some findings were controversial. It was reported that Leu125Val and Ser563Asn PECAM-1 gene polymorphisms were associated with CAD in Germans [18] , Japanese [20] , Chinese in Singapore [21] , Asian Indians in Singapore [22] and in the Chinese Han population [23] . However, in another study with German subjects [19] , the PECAM-1 C/G (Leu125Val) was not an independent risk factor for CAD. In addition, the frequencies of the Leu125Val and Ser563Asn were also not significantly different between a population of Sicilian MI patients and controls, whereas the frequency of the Gly670Arg polymorphism was significantly higher [24] in the MI group. In this study we demonstrated that the PECAM-1 gene polymorphism C373G (Leu125Val) are associated with MI in T2DM patients in the Slovene population (Caucasians). We found the frequency of C allele (125Leu) and the frequency of the CC genotype to be increased in MI patients compared to the control group. Our results are in agreement with that of the Japanese study [20] . Sasaoka and co-workers reported a significantly increased 125Leu (C) allele frequency in MI patients compared to the controls. On the other hand, some other studies reported an increased frequency of the G allele (125Val) in patients with CAD compared to controls [18, 21, 22] . Moreover, it was reported that T2DM patients with no MI diagnosis, are at the same level of MI risk as that of non-diabetic patients with a previous MI [31] diagnosis. It was reported that the direct phosphorylation of PECAM-1, in response to elevated glucose, promotes the transendothelial migration of monocytes [32] . Patients with T2DM exhibited a higher baseline platelet activity and expression of PECAM-1 [33] . But a study in T2DM patients failed to demonstrate any associations between the distribution of PECAM-1 Leu125Val genotypes or allele frequencies and the presence of diabetic retinopathy [34] .
Further studies enrolling larger numbers of patients from different populations are needed to confirm our findings. Namely, genetic association studies are prone to beta statistical error and population-specific genotype effects, all of which make the results difficult to reproduce. In fact, the calculated power of our study for the PECAM polymorphism was 83% taking into account the size of our study sample, and the frequencies of risk allele in cases and controls.
In conclusion, the C373G polymorphism of the PECAM-1 gene is associated with MI in our set of patients. Therefore, this polymorphism might be used as a genetic marker for MI in T2DM in the Slovene population (Caucasians).
